Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B6PZ
|
|||
| Former ID |
DNC004204
|
|||
| Drug Name |
FORMESTANE
|
|||
| Synonyms |
formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Withdrawn from market | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H26O3
|
|||
| Canonical SMILES |
CC12CCC(=O)C(=C1CCC3C2CCC4(C3CCC4=O)C)O
|
|||
| InChI |
1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
|
|||
| InChIKey |
OSVMTWJCGUFAOD-KZQROQTASA-N
|
|||
| CAS Number |
CAS 566-48-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:75172
|
|||
| SuperDrug ATC ID |
L02BG02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aromatase (CYP19A1) | Target Info | Inhibitor | [3] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Estradiol biosynthesis II | ||||
| Estradiol biosynthesis I | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | |||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Reactome | Endogenous sterols | |||
| WikiPathways | Metapathway biotransformation | |||
| Tryptophan metabolism | ||||
| Oxidation by Cytochrome P450 | ||||
| Ovarian Infertility Genes | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| FSH signaling pathway | ||||
| Integrated Breast Cancer Pathway | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000733) | |||
| REF 3 | The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.